Association of MDR1 Gene SNPs and Haplotypes with the Tacrolimus Dose Requirements in Han Chinese Liver Transplant Recipients

Background This work seeks to evaluate the association between the C/D ratios (plasma concentration of tacrolimus divided by daily dose of tacrolimus per body weight) of tacrolimus and the haplotypes of MDR1 gene combined by C1236T (rs1128503), G2677A/T (rs2032582) and C3435T (rs1045642), and to further determine the functional significance of haplotypes in the clinical pharmacokinetics of oral tacrolimus in Han Chinese liver transplant recipients. Methodology/Principal Findings The tacrolimus blood concentrations were continuously recorded for one month after initial administration, and the peripheral blood DNA from a total of 62 liver transplant recipients was extracted. Genotyping of C1236T, G2677A/T and C3435T was performed, and SNP frequency, Hardy-Weinberg equilibrium, linkage disequilibrium, haplotypes analysis and multiple testing were achieved by software PLINK. C/D ratios of different SNP groups or haplotype groups were compared, with a p value<0.05 considered statistically significant. Linkage studies revealed that C1236T, G2677A/T and C3435T are genetically associated with each other. Patients carrying T-T haplotype combined by C1236T and G2677A/T, and an additional T/T homozygote at either position would require higher dose of tacrolimus. Tacrolimus C/D ratios of liver transplant recipients varied significantly among different haplotype groups of MDR1 gene. Conclusions Our studies suggest that the genetic polymorphism could be used as a valuable molecular marker for the prediction of tacrolimus C/D ratios of liver transplant recipients.

[1]  Zi-cheng Yu,et al.  Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  Ying Wang,et al.  Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus , 2009, Nature Genetics.

[3]  Michael M Gottesman,et al.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. , 2009, Biochimica et biophysica acta.

[4]  S. Uemoto,et al.  MDR1 Haplotypes Conferring an Increased Expression of Intestinal CYP3A4 Rather than MDR1 in Female Living-Donor Liver Transplant Patients , 2009, Pharmaceutical Research.

[5]  E. Novotná,et al.  Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients , 2008, Transplantation.

[6]  Shufeng Zhou,et al.  Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[7]  H. Lou,et al.  Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. , 2008, Transplantation proceedings.

[8]  S. Uemoto,et al.  Relation between mRNA Expression Level of Multidrug Resistance 1/ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-Donor Liver Transplantation , 2008, Journal of Pharmacology and Experimental Therapeutics.

[9]  S. Uemoto,et al.  Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients , 2008, Pharmacogenetics and genomics.

[10]  P. Beaune,et al.  Role of Pharmacogenetics of Immunosuppressive Drugs in Organ Transplantation , 2008, Therapeutic drug monitoring.

[11]  D. Brennan,et al.  The role of tacrolimus in renal transplantation , 2008, Expert opinion on pharmacotherapy.

[12]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[13]  T. Liang,et al.  MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation , 2007, Journal of surgical oncology.

[14]  B. Kiberd,et al.  Polymorphisms of Multidrug Resistance Gene (MDR1) and Cyclosporine Absorption in De Novo Renal Transplant Patients , 2007, Transplantation.

[15]  W. Dalton.  Faculty Opinions recommendation of A "silent" polymorphism in the MDR1 gene changes substrate specificity. , 2007 .

[16]  T. Sulikowski,et al.  Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population. , 2007, Pharmacological reports : PR.

[17]  L. Chinn,et al.  ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise , 2007, Clinical pharmacology and therapeutics.

[18]  X. Nie,et al.  Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. , 2006, Transplantation proceedings.

[19]  Zhaoqian Liu,et al.  EFFECTS OF GENETIC POLYMORPHISMS OF CYP3A4, CYP3A5 AND MDR1 ON CYCLOSPORINE PHARMACOKINETICS AFTER RENAL TRANSPLANTATION , 2006, Clinical and experimental pharmacology & physiology.

[20]  W. Sadee,et al.  Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1) , 2006, The AAPS Journal.

[21]  G. Luleci,et al.  The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. , 2006, Transplantation proceedings.

[22]  Zhen Shu-sen,et al.  Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  S. Masuda,et al.  Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living‐donor liver transplant patients , 2006, Clinical pharmacology and therapeutics.

[24]  Yong Wang,et al.  Relationship between MDR1 polymorphism and blood concentration of cyclosporine A. , 2005, Chinese medical journal.

[25]  Andrew D. Johnson,et al.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability , 2005, Pharmacogenetics and genomics.

[26]  U. Gündüz,et al.  Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients , 2005, American journal of hematology.

[27]  Min Goo Lee,et al.  Gene SNPs and mutations in clinical genetic testing: haplotype-based testing and analysis. , 2005, Mutation research.

[28]  S. Masuda,et al.  Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. , 2005, Transplantation proceedings.

[29]  P. Beaune,et al.  Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[31]  B. Meibohm,et al.  Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. , 2004, International journal of clinical pharmacology and therapeutics.

[32]  Daniel O Stram,et al.  Tag SNP selection for association studies , 2004, Genetic epidemiology.

[33]  A. Clark,et al.  The role of haplotypes in candidate gene studies , 2004, Genetic epidemiology.

[34]  M. Droździk,et al.  P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. , 2004, Journal of clinical periodontology.

[35]  R. Farinotti,et al.  MDR-1 C3435T Polymorphism Influences Cyclosporine A Dose Requirement in Liver-Transplant Recipients , 2004, Transplantation.

[36]  S. Masuda,et al.  CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.

[37]  D. Tregouet,et al.  CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation , 2004, Clinical pharmacology and therapeutics.

[38]  Chava Kimchi-Sarfaty,et al.  P-glycoprotein: from genomics to mechanism , 2003, Oncogene.

[39]  T. Nabeshima,et al.  Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1 , 2003, Transplantation.

[40]  P. Beaune,et al.  Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. , 2003, Journal of the American Society of Nephrology : JASN.

[41]  E. Lee,et al.  Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. , 2003, British journal of clinical pharmacology.

[42]  B. Meibohm,et al.  The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients , 2003, Journal of clinical pharmacology.

[43]  E. Schuetz,et al.  Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  Y. Cheung,et al.  Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. , 2003, Pharmacogenetics.

[45]  V. Ribeiro,et al.  CYP3A4 and MDR1 Alleles in a Portuguese Population , 2003, Clinical chemistry and laboratory medicine.

[46]  S. Higuchi,et al.  Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. , 2001, Pharmacogenetics.

[47]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Ge Zhang,et al.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. , 2008, Drug metabolism reviews.

[49]  K. Iwasaki.  Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. , 2007, Drug metabolism and pharmacokinetics.

[50]  R. Watanabe,et al.  Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. , 2006, Transplant immunology.

[51]  O. Slanař,et al.  Polymorphisms of the MDR1 gene in the Czech population. , 2006, Folia biologica.

[52]  L. Domański,et al.  MDR 1 gene polymorphism in allogenic kidney transplant patients with tremor , 2005 .